Clinical Trials DEA Food 
SpeedWeed
MAY 15, 2021
A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The post Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD appeared first on SpeedWeed. Image via.
SpeedWeed
SEPTEMBER 4, 2021
The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. View original article.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
MARCH 1, 2019
” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue. .
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial. Let us know in the comments!
Canna Law Blog
JANUARY 3, 2023
There has been so much talk from the Food and Drug Administration (“FDA”) around cannabidiol (“CBD”) regulations that it makes one’s head spin. Now though, it sounds like FDA is serious about CBD regulations in the context of both food and supplements. A little CBD history. 2018 Farm Bill.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.
Cannabis Law Report
MARCH 18, 2022
Food and Drug Administration (FDA) guidance on clinical trials, Drug Enforcement Agency (DEA) licensing, material transfer agreements and cooperative research and development agreements (CRDA). The firm’s multidisciplinary team covers commercial, regulatory and legal requirements spanning U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content